Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients. Provided here is a review of the existing data and guidelines in the European Union, relating to recommendations, as well as considerations, for the referral of OC patients for BRCA genetic testing. Based on this review of newly updated guidance and up-to-date evidence, the following is recommended: all patients with invasive epithelial OC (excluding borderline or mucinous), including those with fallopian tube and peritoneal cancers, should be considered as candidates for referral for BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at diagnosis, although patients can be referred at any stage; retrospective testing should be offered to patients in long-term follow-up because of the implications for family members and individual future breast cancer risk; and germline BRCA testing of a blood/saliva sample should initially be conducted and, if negative, tumour tissue should be tested (to identify non-germline [somatic] BRCA PARPi therapy candidates).

Vergote, I., Banerjee, S., Gerdes, A., van Asperen, C., Marth, C., Vaz, F., et al. (2016). Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. EUROPEAN JOURNAL OF CANCER, 69, 127-134 [10.1016/j.ejca.2016.10.006].

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients

COLOMBO, NICOLETTA
Ultimo
2016

Abstract

Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients. Provided here is a review of the existing data and guidelines in the European Union, relating to recommendations, as well as considerations, for the referral of OC patients for BRCA genetic testing. Based on this review of newly updated guidance and up-to-date evidence, the following is recommended: all patients with invasive epithelial OC (excluding borderline or mucinous), including those with fallopian tube and peritoneal cancers, should be considered as candidates for referral for BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at diagnosis, although patients can be referred at any stage; retrospective testing should be offered to patients in long-term follow-up because of the implications for family members and individual future breast cancer risk; and germline BRCA testing of a blood/saliva sample should initially be conducted and, if negative, tumour tissue should be tested (to identify non-germline [somatic] BRCA PARPi therapy candidates).
Articolo in rivista - Articolo scientifico
BRCA1; BRCA2; Genetic testing; Guidelines; Ovarian cancer; PARPi;
BRCA1; BRCA2; Genetic testing; Guidelines; Ovarian cancer; PARPi; Oncology; Cancer Research
English
127
134
8
Vergote, I., Banerjee, S., Gerdes, A., van Asperen, C., Marth, C., Vaz, F., et al. (2016). Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. EUROPEAN JOURNAL OF CANCER, 69, 127-134 [10.1016/j.ejca.2016.10.006].
Vergote, I; Banerjee, S; Gerdes, A; van Asperen, C; Marth, C; Vaz, F; Ray Coquard, I; Stoppa Lyonnet, D; Gonzalez Martin, A; Sehouli, J; Colombo, N
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/139504
Citazioni
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 37
Social impact